Juniper Biologics Pte. Ltd. v Ramandeep Singh

Juniper Biologics Pte Ltd (JBPL), a wholesaler of pharmaceutical products, was incorporated in September 2020 by the defendant, Mr Ramandeep Singh, who also set up its affiliate Juniper Therapeutix Pte Ltd. After the Sylvan Group became majority shareholder in December 2021, Mr Singh served as CEO until the Board terminated his appointment on 4 July 2024. In Originating Claim No 695 of 2024, filed on 5 September 2024, JBPL sued him for alleged breaches of his contractual and general duties, principally the duty to act in its best interests.

By Summons No 1163 of 2026, JBPL applied to amend its Statement of Claim on four heads. The Ledaga Claim alleged that Mr Singh's conduct left JBPL unable to make a US$5m milestone payment to Helsinn, which terminated the Ledaga Agreement on 27 May 2024; the agreement was reinstated by an amendment agreement on 1 August 2024. JBPL wanted to add that it later failed to pay an instalment due on 30 June 2025 and that Helsinn terminated the amendment agreement on 1 July 2025. The Xocova Claim alleged that Mr Singh caused Juniper Therapeutix to enter a commercially unviable licence for a COVID-19 drug; JBPL sought to add particulars, later developments and that company's losses. The Bonus Claim amendments alleged that he inflated revenue to obtain a US$600,000 bonus. The Expenses Claim amendments pleaded a new period and total for allegedly unjustified expenses without a breakdown. The application was heard by an Assistant Registrar.

1. Whether the Ledaga Amendments impermissibly introduced facts arising after the claim was filed, and how O 9 r 14(2) of the Rules of Court 2021 applies.
2. Whether the Ledaga and Xocova Amendments disclosed a reasonable cause of action.
3. Whether the Bonus Amendments introduced a new cause of action or were factually unsustainable.
4. Whether the Expenses Amendments, which replaced the particulars with an unexplained total, should be allowed.

The court accepted that the three-step framework in Wang Piao v Lee Wee Ching [2024] 4 SLR 540 applied. On post-filing facts, it held that the old Relation Back Rule still governed: an amendment cannot plead a cause of action that did not exist when the pleading was filed, or complete an incomplete one, but later facts going to remedy on an existing cause of action may be added. It rejected both parties' premise that O 9 r 14(2) governs amendments. Read against its text, the structure of the rule and the reform reports, that sub-rule lets the court in a special case consider unpleaded later events without amendment; ordinary amendments fall under O 9 r 14(1). The Ledaga Claim was complete when filed, and the later events only showed the alleged loss taking its final form after failed mitigation, so the amendments went to remedy.

On causation, Mr Singh argued he had no part in the amendment agreement. The court found this misread JBPL's case, which located the loss in the missed payment, and held the case arguable. For Xocova, an amendment liable to be struck out cannot be allowed, but because breach of contract is actionable without proof of damage, particulars of the agreements could go to breach. Loss suffered only by Juniper Therapeutix, and its later mitigation efforts, did not bear on any issue between JBPL and Mr Singh, so those parts were refused.

The bonus conduct and payment predated the claim, so even a new cause of action did not offend the Relation Back Rule, and the audited accounts and chairman's email did not show that the allegation of inflated figures was plainly unsustainable. For expenses, inconsistency with earlier particulars was not itself fatal, but deleting the particulars without replacing them would leave Mr Singh unable to know which expenses were challenged, so further particulars were directed.

The court allowed the application in part. It allowed the Ledaga Amendments and the Bonus Amendments in full, allowed the Xocova Amendments only as to paras 42(c) and 42(d) of the Statement of Claim, and allowed the Expenses Amendments on the direction that JBPL add further particulars of the revised claim. JBPL was ordered to file and serve its amended Statement of Claim within 14 days, with costs to be agreed or decided on written submissions.